VivoSeq
Other

ASCVD

0

Pipeline Programs↗

3

Active Trials↗

1

Companies Involved↗

ASCVD is an early-stage landscape with 0 programs across 1 company. The most active players are Novartis.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

4

clinical trials

Active, not recruiting2 · 50%
Recruiting1 · 25%
Completed1 · 25%

Clinical Trials

Trial Activity

Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD
Active, not recruiting·Novartis logoNovartis·Phase 3·NCT06267560·422 enrolled
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
Recruiting·Novartis logoNovartis·Phase 3·NCT06813911·340 enrolled
Adherence to Dyslipidemia Therapy: Harnessing Evidence From Randomized Evaluations in AtheroSclerotic CardioVascular Disease (ADHERE-ASCVD)
Active, not recruiting·—·Preclinical·NCT07522645·22,000 enrolled
A Cluster-randomized Trial to Improve Use of High IntEnsity Statins for Vascular Protection
Completed·DDuke University·N/A·NCT06551701·225 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)